)
Visual21 Nov 2025
Data center suppliers
Nurix Therapeutics (NRIX) investor relations material
Nurix Therapeutics Jefferies London Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Jefferies London Healthcare Conference 2025 summary19 Nov, 2025
Key clinical updates and data disclosures
Upcoming ASH presentation will feature long-term data on bexobrutideg and NX-5948, including progression-free survival and duration of response, with some patients on therapy for over two years.
600 mg once-daily dose of bexobrutideg selected for pivotal CLL trial, supported by FDA agreement and similar safety profile to lower doses.
Bexobrutideg shown to degrade all BTK resistance mutations, addressing a major challenge in CLL treatment.
Pivotal study focuses on triple-exposed CLL patients, a group with high unmet need and no approved therapies.
Confirmatory randomized trial will target second-line CLL, aiming for full approval in a market of over 10,000 patients annually.
Competitive landscape and future plans
ASH session will include presentations from competing BTK degraders, with attention on comparative efficacy and response rates.
Plans to initiate combination trials with bexobrutideg and agents like venetoclax, anti-CD20 antibodies, and bispecific antibodies.
Monitoring progress in NHL and planning to present data as patient cohorts mature.
Ongoing planning for global phase III trial with multiple control arms to accommodate regional standards.
Regulatory feedback and control arm composition are under active discussion for the pivotal trial.
Platform expansion and pipeline partnerships
BTK degrader platform being extended to autoimmune diseases, with a new formulation in multiple ascending dose studies and IND planned for 2026.
Early clinical work includes CLL patients with autoimmune hemolytic anemia and CNS involvement, with enrollment ongoing.
Strong rationale for BTK degradation in MS, supported by CNS penetration and preclinical data showing high BTK removal in microglia.
IRAK4 degrader (GS-6791, with Gilead) in phase I; STAT6 degrader (NX-3911, with Sanofi) in IND-enabling studies, both showing promising safety and potency.
Multiple partnership options with opt-in rights after human proof of concept, with key decisions expected from 2026 onward.
How does 600mg dose maximize Bexobrutideg efficacy?
What is Bexobrutideg's potential in CNS autoimmune?
How will Nurix decide on partnership opt-ins?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Nurix Therapeutics earnings date
Q4 202513 Feb, 2026
Next Nurix Therapeutics earnings date
Q4 202513 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule and cell therapies. These therapies are designed to treat cancer and inflammatory diseases by modulating cellular protein levels. Nurix leverages its proprietary DELigase platform, which involves the use of E3 ligases within the ubiquitin-proteasome system, to either decrease or increase protein levels selectively. The company’s drug development strategy includes both targeted protein degraders and ligase inhibitors, addressing unmet medical needs in hematology-oncology, immuno-oncology, and inflammation. The company is headquartered in San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage